MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461483 | Name: Panipenem

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Panipenem is a carbapenem antibiotic used in combination with betamipron.

Chemical Structure

Panipenem
Panipenem
CAS#87726-17-8

Theoretical Analysis

MedKoo Cat#: 461483

Name: Panipenem

CAS#: 87726-17-8

Chemical Formula: C15H21N3O4S

Exact Mass: 339.1253

Molecular Weight: 339.41

Elemental Analysis: C, 53.08; H, 6.24; N, 12.38; O, 18.86; S, 9.45

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Panipenem; CS 533; CS-533; CS533; RS 533; RS-533; RS533;
IUPAC/Chemical Name
(5R,6S)-6-((R)-1-hydroxyethyl)-3-(((S)-1-(1-iminoethyl)pyrrolidin-3-yl)thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
InChi Key
TYMABNNERDVXID-DLYFRVTGSA-N
InChi Code
InChI=1S/C15H21N3O4S/c1-7(19)12-10-5-11(13(15(21)22)18(10)14(12)20)23-9-3-4-17(6-9)8(2)16/h7,9-10,12,16,19H,3-6H2,1-2H3,(H,21,22)/t7-,9+,10-,12-/m1/s1
SMILES Code
O=C(C(N12)=C(S[C@@H]3CN(C(C)=N)CC3)C[C@]2([H])[C@@H]([C@H](O)C)C1=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 339.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kato A, Ueyama J, Abe F, Hotta K, Tsukiyama I, Oshima T, Kondo F, Saito H, Hasegawa T. Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats. Anticancer Res. 2011 Sep;31(9):2915-22. PubMed PMID: 21868538. 2: Nakagawa Y, Suzuki K, Ohta K, Hino M, Ohyashiki K, Kanamaru A, Tamura K, Urabe A, Masaoka T; Japan Febrile Neutropenia Study Group. Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia. J Infect Chemother. 2013 Feb;19(1):103-11. doi: 10.1007/s10156-012-0466-8. Epub 2012 Sep 5. PubMed PMID: 22948387. 3: Suzuki H, Tokuda Y, Shichi D, Hitomi S, Ishikawa H, Maeno T, Nakamura H. A retrospective cohort study of panipenem/betamipron for adult pneumococcal bacteremia at three teaching hospitals in Japan. J Infect Chemother. 2013 Aug;19(4):607-14. doi: 10.1007/s10156-012-0525-1. Epub 2012 Dec 1. PubMed PMID: 23203218. 4: Ji J, Du X, Chen Y, Fu Y, Wang H, Yu Y. In vitro activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii. Int J Antimicrob Agents. 2013 Apr;41(4):400-1. doi: 10.1016/j.ijantimicag.2012.12.014. Epub 2013 Feb 12. PubMed PMID: 23410789. 5: Clinical Trial Research Group on Panipenem-betamipron. [The clinical efficacy and safety of panipenem-betamipron in treatment of moderate to severe pulmonary infection]. Zhonghua Nei Ke Za Zhi. 2012 Jul;51(7):547-50. Chinese. PubMed PMID: 22943829. 6: Goa KL, Noble S. Panipenem/betamipron. Drugs. 2003;63(9):913-25; discussion 926. Review. PubMed PMID: 12678575. 7: Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother. 2004 Apr;48(4):1159-67. PubMed PMID: 15047516; PubMed Central PMCID: PMC375245. 8: Ohashi N, Uematsu T, Nagashima S, Kanamaru M, Tajima N, Togawa A, Hishida A. Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease. J Infect Chemother. 2005 Feb;11(1):24-31. PubMed PMID: 15729484. 9: Kwon KT, Cheong HS, Rhee JY, Wi YM, Ryu SY, Heo ST, Moon CS, Ki HK, Kim KH, Jung CW, Peck KR, Song JH. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial. Jpn J Clin Oncol. 2008 Jan;38(1):49-55. doi: 10.1093/jjco/hym151. Epub 2008 Jan 17. PubMed PMID: 18203711. 10: Kojima S, Nadai M, Kitaichi K, Wang L, Nabeshima T, Hasegawa T. Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. Antimicrob Agents Chemother. 1998 Dec;42(12):3136-40. PubMed PMID: 9835504; PubMed Central PMCID: PMC106012. 11: Tajima N, Ishizuka H, Naganuma H. Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function. Chemotherapy. 2006;52(5):245-53. Epub 2006 Jul 25. PubMed PMID: 16864999. 12: Li JJ, Jia YQ, Cui X, Huang J, He C. [Preliminary clinical evaluations of panipenem-betamipron in the treatment of hematological malignancy infections]. Zhonghua Yi Xue Za Zhi. 2012 Feb 21;92(7):452-5. doi: 10.3760/cma.j.issn.00376-2491-2012.07.006. Chinese. PubMed PMID: 22490964. 13: Ito N, Suzuki M, Kusai A, Takayama K. Effect of initial concentration on stability of panipenem in aqueous solution. Chem Pharm Bull (Tokyo). 2005 Mar;53(3):323-7. PubMed PMID: 15744107. 14: Fukuoka T, Ohya S, Narita T, Katsuta M, Iijima M, Masuda N, Yasuda H, Trias J, Nikaido H. Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother. 1993 Feb;37(2):322-7. PubMed PMID: 8452364; PubMed Central PMCID: PMC187661. 15: Kaku M. [Adequate use of parenteral antibacterial agents: panipenem/betamipron (discussion)]. Jpn J Antibiot. 2012 Apr;65(2):99-110. Japanese. PubMed PMID: 22970633. 16: Kimura T, Kokubun H, Nowatari M, Matsuura N, Sunakawa K, Kubo H. Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage. J Antimicrob Chemother. 2001 Jan;47(1):51-9. PubMed PMID: 11152431. 17: Kurihara A, Hisaoka M, Mikuni N, Kamoshida K. Neurotoxicity of panipenem/betamipron, a new carbapenem, in rabbits: correlation to concentration in central nervous system. J Pharmacobiodyn. 1992 Jul;15(7):325-32. PubMed PMID: 1447679. 18: Shimada J, Kawahara Y. Overview of a new carbapenem, panipenem/betamipron. Drugs Exp Clin Res. 1994;20(6):241-5. PubMed PMID: 7758396. 19: Tajima N, Soma M, Ishizuka H, Naganuma H. Quantitative evaluation of effect of renal failure on the pharmacokinetics of panipenem in rats. Biol Pharm Bull. 2005 Nov;28(11):2170-2. PubMed PMID: 16272714. 20: Hayakawa M, Ito Y, Fujita I, Iseki K, Gando S. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study. ASAIO J. 2006 Jul-Aug;52(4):398-403. PubMed PMID: 16883119.

View History

ZINC08383544

ZINC08383544